Where strongyloidiasis is common enough that ivermectin should be added to school deworming
- Good it would do
- 2 / 5
- Can AI help
- 2 / 5
- How neglected
- 3 / 5
- Can we check it
- 3 / 5
Why it's on hold
Parked: the gap is real (WHO's 2024 guideline needs prevalence data that are scarce, and no mass programmes exist), but most published surveys used stool tests so insensitive that, once corrected, they straddle WHO's 10% true-prevalence line; the one dense national dataset (Cambodia) showed little gain from spatial modelling; and funded groups (Stanford Cote d'Ivoire, Western Pacific 1 km map) are close. The scout's school-only framing is also out of date: WHO recommends whole-community treatment.
Why it's stuck
A 2020 global estimate put the number of infected people at about 614 million in 2017 (8.1 percent of the world), with a very wide range of 313 to 910 million. The authors describe the burden as highly uncertain: the estimate rests on studies from 1990 to 2016 that had to be corrected for weak diagnostic tests, and countries with little data were filled in by a statistical model.
What we'd try
Pool every published prevalence survey, correct each for the accuracy of the test it used, and fit a fine-grained geostatistical model with climate, soil, sanitation and household survey data to map prevalence at district level with honest uncertainty. The check is to hold back surveys by country and see how well the map predicts them, and later to compare with new surveys that use the better blood tests.
We'd look again if
Any one of: (1) a decidability audit on the West Africa study-level data shows a good share of school-age surveys sit clearly above or below WHO's 10% true-prevalence line after test correction, and the Negrar, Stanford and Western Pacific teams confirm they are not covering the same countries; (2) district-level surveys with good tests (Baermann, agar plate or quality-assured serology) become public for a middle-prevalence country outside onchocerciasis, filariasis and Loa loa areas, such as the Ethiopia 33-woreda serology or the Stanford Cote d'Ivoire data; (3) a national programme or WHO's NTD department names a country where it would use a model to choose where to survey.
Think we got it wrong?
Ruled-out problems can come back. Tell us what we missed.
Members can read the full record for this problem, check its sources and comment. Open the member view →